Antiretroviral Therapy Cohort Collaboration

Size: px
Start display at page:

Download "Antiretroviral Therapy Cohort Collaboration"

Transcription

1 Antiretroviral Therapy Cohort Collaboration nd Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 2015 Margaret May, A Trickey, D Costagliola, P Reiss, S Moreno, MJ Gill, C Smith, S Ingle, J Sterne, on behalf of the ART-CC. Association of CD4:CD8 with Cause-specific Mortality in 20,464 Patients on Long Term ART. Poster presentation Suzanne Ingle, JM Miro, H Furrer, A Justice, MS Saag, C Manzardo, A Esteve, L Cain, J Sterne, M May on behalf of ART-CC, COHERE in EuroCoord, CNICS and NA- ACCORD. Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings. Themed discussion st Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 2014 Michael Mugavero, A Westfall, J Gill, M Saag, S Abgrall, G Fatkenheuer, P Reiss, S Ingle, M May, J Sterne on behalf of the ART-CC. Cumulative viral load predicts all-cause and AIDSrelated mortality after initiation of ART. Poster presentation. Marie-Anne Vandenhende, S Ingle, M May, M Cavassini, A Mocroft, P Reiss, J Tate, H Crane, J Sterne, G Chêne on behalf of the ART-CC. Impact of Low-Level Viremia on Clinical and Virological Outcomes in Treated HIV Infected Patients. Poster presentation. Marie Helleberg, M May, JAC Sterne & N Obel for ART-CC. Impact of Smoking on Life Expectancy among HIV-Infected Individuals: The ART Cohort Collaboration. Poster presentation th Conference on Retroviruses and Opportunistic Infections, Atlanta, USA, March 2013 Andrew Boulle, M Schomaker, M May, M Egger, J Sterne, and site investigators from IeDEA-SA and ART-CC Collaboration. Mortality after Starting ART in Treatment-naïve Adults in 3 Continents: Collaborative Analysis of International Epidemiologic Databases to Evaluate AIDS in Southern Africa and ART Cohort Collaboration Cohorts. Oral presentation. Margaret May, M Gill, R Harrigan, M Klein, P Reiss, A Mocroft, A d Arminio Monforte, R Zangerle, M Cavassini, J Sterne, and ART Cohort Collaboration. Mortality of Treated HIV-1

2 Positive Individuals According to Viral Subtype in Europe and Canada: Antiretroviral Therapy Cohort Collaboration (ART-CC). Poster presentation. Margaret May, A Mocroft, J Guest, H Crane, P Reiss, A d Arminio Monforte, P Labarga, J-C Wasmuth, S Ingle, R Hogg, and ART Cohort Collaboration. Contribution of AIDS and Non- AIDS Deaths to Lower Life Expectancy of ART Treated HIV Positive Individuals Compared with the General Population. Poster presentation. Suzanne Ingle, T Glass, H Crane, R Hogg, J Gill, A Ammassari, M Mugavero, J Tate, N Turner, J Sterne, and ART Cohort Collaboration. Associations of Self-reported and Prescription-based Adherence with Viral Suppression in Five HIV Cohort Studies. Poster presentation. 8th International Conference on HIV Treatment and Prevention Adherence, Miami, USA, June 2013 Suzanne M Ingle, TR Glass, HM Crane, RS Hogg, MJ Gill, A Ammassari, MJ Mugavero, J Tate, NL Turner, MT May, JAC Sterne. Defining self-reported and prescription measures of adherence to ART: multi-cohort analysis. Poster presentation. Nicholas L Turner, SM Ingle, RS Hogg, MJ Gill, J Tate, HM Crane, TR Glass, A Ammassari, M Saag, M Mugavero, MT May, JAC Sterne. Association of time-varying adherence to ART on rates of AIDS/death: cross-cohort analysis. Poster presentation th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, March 2012 Catrina Mugglin, K Althoff, K Wools-Kaloustian, J Sterne, D Nash, F Dabis, C Williams, C McGowan, D Cooper, Matthias Egger, and IeDEA and ART-CC Collaborations. Immunodeficiency at the start of ART: Global view. Oral presentation. Sophie Abgrall, S Ingle, M Saag, M Cavassini, R Hogg, H Crane, M May, J Sterne, and the Antiretroviral Therapy Cohort Collaboration (ART-CC). Cumulative incidence of and risk factors for changes to first ART regimen and death prior to a change: the Antiretroviral Therapy Cohort Collaboration (ART-CC). Poster presentation. Suzanne Ingle, J Gill, M Mugavero, C Lewden, S Abgrall, G Fätkenheuer, P Reiss, M May, J Sterne, M Saag, and The Antiretroviral Therapy Cohort Collaboration (ART-CC). Distribution of age at death and effects of immunosuppression and ART duration vary according to cause of death in HIV-1 positive people. Poster presentation. 2011

3 International AIDS Society Conference (IAS), Rome, Italy, July 2011 Inma Jarrin on behalf of the ART Cohort Collaboration (ART-CC). Sex differences in mortality rates among HIV-positive patients: The Antiretroviral Therapy Cohort Collaboration (ART-CC). 18th Conference on Retroviruses and Opportunistic Infections, Boston, USA, Feb 2011 Inma Jarrin, Julia del Amo and the ART Cohort Collaboration (ART-CC). Differences in mortality rates among treated patients according to geographical origin and ethnicity/race. Sophie Abgrall, R Cornish, MMugavero, M Saag, M May, J Sterne and the ART Cohort Collaboration. Outcomes after switch from or interruption to first ART regimen th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, Canada, Feb 2009 Jonathan Sterne and the ART Cohort Collaboration (ART-CC). When should HIV-1 infected persons initiate antiretroviral therapy? Collaborative analysis of HIV Cohort Studies John Gill and the ART Cohort Collaboration (ART-CC). Causes of Death in Patients Treated with ART, 1996 to 2006: Collaborative Analysis of 13 Cohort Studies th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, Feb 2008 Michael Mugavero, Margaret May, Heather Ribaudo, Jonathan Sterne, Sonia Napravnik, Matthias Egger, Michael Saag, Roy Gulick. Outcomes of Abacavir and Efavirenz based HAART: Comparison of ACTG 5095 Trial Results with Observational Cohort Studies th Conference on Retroviruses and Opportunistic Infections (CROI), Los Angeles, USA, Feb 2007 Matthias Egger. Plenary: Outcomes of ART in Resource-Limited and Industrialized Countries Amanda Mocroft and the ART Cohort Collaboration (ART-CC). Clinical Endpoints for Randomized Clinical Trials: All AIDS-defining Conditions Are Not Created Equal Jonathan Sterne and the ART Cohort Collaboration (ART-CC). Prognosis of Patients Treated with cart from 36 Months after Initiation of Therapy, according to Current and Previous CD4 Cell Count Michael Mugavero and the ART Cohort Collaboration (ART-CC). A Comparison of Commonly Prescribed cart Regimens: Do Differences in Short-term Virologic Success Translate to Better Clinical Outcomes?

4 Robert Hogg and the ART Cohort Collaboration (ART-CC). Life Expectancy of Persons at the Time of Initiating cart in Hgh-income Countries th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, USA, Feb 2006 Jonathan Sterne, M May, D Costagliola, M Egger, R Hogg, A D'Arminio Monforte, G Chene, M Gill, F De Wolf, S Cole, and ART Cohort Collaboration. Estimating the Optimum CD4 Threshold for Starting HAART in ART-naïve HIV-infected Individuals Robert Hogg, J Lundgren, D Costagliola, A Monforte, B Ledergerber, F de Wolf, G Fusco, S Staszewski, G Chêne, A Phillips, J Gill, J Rockstroh, M May, J Sterne, M Egger, and ART Cohort Collaboration. Mortality Rates According to Initial HAART Regimen: A Collaborative Analysis of 12 Prospective Cohort Studies Caroline Sabin, Antonella D'Arminio Monforte, Margaret May, Sophie Grabar, Peter Reiss, Jens Lundgren, Amy Justice, Schlomo Staszewski, Catherine Leport, Francois Dabis, Julio S.G. Montaner, Margaret Johnson, M John Gill, Gerd Fatkenheuer, Matthias Egger and the ART Cohort Collaboration. The Changing Incidence of Clinical AIDS Events in 12,574 Treatment-naive Patients Starting HAART th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, Feb 2005 Robert Hogg, J Lundgren, D Costagliola, A Monforte, B Ledergerber, F De Wolf, G Fusco, S Staszewski, G Chêne, A Phillips, J Gill, J Rockstroh, M May, J Sterne, M Egger and ART- CC. Mortality rates according to initial HAART regimen: a collaborative analysis of 12 prospective cohort studies. Francois Dabis, M Schechter, M Egger, and ART-LINC/ART-CC Study Groups. Response to Highly Active Antiretroviral Therapy in low- and high-income countries: Analysis of clinical databases from 4 continents International AIDS Conference 2004, Bangkok, July 2004 Margaret May and Jonathan Sterne for ART-CC. Changes in the effect of prognostic factors with time on HAART: ART Cohort Collaboration th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, Feb 2003 J. A. C. Sterne, M. May, D. Costagliola, P. Pezzotti, B. Ledergerber, F. de Wolf, J. Lundgren, J. S. Fusco, S. Staszewski, F. Raffi, R. S. Hogg, A. N. Phillips, M. J. Gill, G. Fatkenheuer, G. Chêne and ART-CC. Does it matter where you came from? Prognosis of patients starting potent therapy, according to initial response.

5 2002 AIDS Conference, Barcelona, July 2002 M May, J A C Sterne, D Costagliola, P Pezzotti, B Ledergerber, F de Wolf, J D Lundgren, A C Justice, V Miller, G Chêne, F Dabis, R S Hogg, C Sabin, M J Gill, B Salzberger, M Egger. Construction and validation of a prognostic model for progression to AIDS or death in drugnaïve patients starting potent antiretroviral therapy. ART Cohort Collaboration. G Chêne, M May, D Costagliola, A d'arminio Monforte, C Junghans, F de Wolf, J D Lundgren, G Fusco, V Miller, C Leport, F Dabis, R S Hogg, A N Phillips, M J Gill, B Salzberger, J A C Sterne, M Egger. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. ART Cohort Collaboration.

University of Bristol - Explore Bristol Research

University of Bristol - Explore Bristol Research May, M. T., Vehreschild, J-J., Trickey, A., Obel, N., Reiss, P., Bonnet, F.,... The Antiretroviral Therapy Cohort Collaboration (ART-CC) (2016). Mortality according to CD4 count at start of combination

More information

European Guidelines. for the Clinical Management and Treatment of HIV Infected Adults

European Guidelines. for the Clinical Management and Treatment of HIV Infected Adults European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005 These Euroguidelines result from the comparison of guidelines from several European countries and from a discussion

More information

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies When To Start Consortium* Summary Background The CD4 cell count at

More information

The importance of cohort collaborations for guiding clinical management of individuals with HIV infection

The importance of cohort collaborations for guiding clinical management of individuals with HIV infection The importance of cohort collaborations for guiding clinical management of individuals with HIV infection Caroline Sabin Professor of Medical Statistics and Epidemiology Royal Free and University College

More information

TB e HIV nelle coorti

TB e HIV nelle coorti TB e HIV nelle coorti Antonella d Arminio Monforte Clinica di Malattie Infettive Dipartimento di Scienze della Salute Università degli Studi di Milano Presidio Ospedalero San Paolo, ASST Santi Paolo e

More information

Lack of association between use of efavirenzand death from suicide: the D:A:D Study

Lack of association between use of efavirenzand death from suicide: the D:A:D Study Lack of association between use of efavirenzand death from suicide: the D:A:D Study Colette Smith, Lene Ryom, Antonellad ArminioMonforte, Peter Reiss, Amanda Mocroft, Wafaa el Sadr, Rainer Weber, Mathew

More information

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies The Antiretroviral Therapy Cohort Collaboration* Summary Background Health

More information

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies Survival of HIV-positive patients starting antiretroviral therapy between 996 and 203: a collaborative analysis of cohort studies The Antiretroviral Therapy Cohort Collaboration* Summary Background Health

More information

University of Bristol - Explore Bristol Research

University of Bristol - Explore Bristol Research Trickey, A., May, M. T., Schommers, P., Tate, J., Ingle, S. M., Guest, J. L.,... Sterne, J. A. C. (2017). CD4:CD8 ratio and CD8 count as prognostic markers for mortality in HIV-positive patients on ART:

More information

Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study

Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study Collins Iwuji, Duncan Churchill, Yvonne Gilleece, Martin Fisher Brighton and

More information

Titile: Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

Titile: Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord Titile: Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord Author List: COHERE in EuroCoord* 1 1 1 1 0 1 0 1 Corresponding author: Geneviève Chêne,

More information

[RH], ; 95% ; P

[RH], ; 95% ; P 1086 Human Immunodeficiency Virus Rebound after Suppression to!400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of Suppression

More information

Time to First-line ART Failure and Switch to Second-line ART in the IeDEA Pediatric Cohort

Time to First-line ART Failure and Switch to Second-line ART in the IeDEA Pediatric Cohort Time to First-line ART Failure and Switch to Second-line ART in the IeDEA Pediatric Cohort K. Wools-Kaloustian, S. Li, B. Musick, I. Marete, S. Ayaya, A. Sohn, L. Nguyen, V. Leroy, F. Eboua, J. Newman,

More information

To interrupt or not to interrupt Are we SMART enough?

To interrupt or not to interrupt Are we SMART enough? SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis

More information

Harvard University Affiliated Abstract Presentations at CROI

Harvard University Affiliated Abstract Presentations at CROI BOSTON, MASSACHUSETTS February 22 25, 2016 Harvard University Affiliated Abstract Presentations at CROI This table represents abstracts reported to the Harvard University Center for AIDS Research by members

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This supplementary Appendix accompanies the article Cost-Effectiveness of HIV Monitoring Strategies in Resource-Limited Settings (Archives of Internal Medicine, September 22, 2008),

More information

Perspective Current Concepts in Antiretroviral Therapy Failure

Perspective Current Concepts in Antiretroviral Therapy Failure International AIDS Society USA Perspective Current Concepts in Antiretroviral Therapy Failure Currently, the goal for the first and second, and possibly the third, antiretroviral regimen is the suppression

More information

Articles. Funding HAART Oversight Committee.

Articles. Funding HAART Oversight Committee. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration D:A:D Study Group* Summary Background

More information

The Incidence of AIDS-Defining Illnesses at a Current CD4 Count 200 Cells/µL in the Post Combination Antiretroviral Therapy Era

The Incidence of AIDS-Defining Illnesses at a Current CD4 Count 200 Cells/µL in the Post Combination Antiretroviral Therapy Era Clinical Infectious Diseases Advance Access published August 6, 2013 MAJOR ARTICLE HIV/AIDS The Incidence of AIDS-Defining Illnesses at a Current CD4 Count 200 Cells/µL in the Post Combination Antiretroviral

More information

Many highly active antiretroviral therapy PROCEEDINGS

Many highly active antiretroviral therapy PROCEEDINGS MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: IS THERE A ROLE FOR QUADRUPLE REGIMENS? * François Raffi, MD, PhD ABSTRACT Although many highly active antiretroviral therapy (HAART)

More information

JMSCR Vol 3 Issue 10 Page October 2015

JMSCR Vol 3 Issue 10 Page October 2015 www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x DOI: http://dx.doi.org/10.18535/jmscr/v3i10.20 Drugs Related Changes of Haemoglobin and CD4 Counts in HIV-Infected Patients on Antiretroviral

More information

Cascade of medical care to HIV-infected patients in Europe. Cristina Mussini

Cascade of medical care to HIV-infected patients in Europe. Cristina Mussini Cascade of medical care to HIV-infected patients in Europe Cristina Mussini UNAIDS: New HIV treatment target 90% of people tested 90% of people diagnosed with HIV on treatment 90% of people on treatment

More information

Antiviral Therapy 13:77 85

Antiviral Therapy 13:77 85 Original article Antiviral Therapy 13:77 85 Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients Tracy

More information

3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #

3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract # 3rd IAS Conference on HIV Pathogenesis and Treatment 24 27 July 2005, Rio de Janeiro, Brazil Poster Number Abstract # TuFo0106 TuFo0106 Characterization of Anemia in HIV-infected (HIV+) Subjects Treated

More information

1. PICO question. Interventions Reference standard or comparators Outcomes. Study design Other

1. PICO question. Interventions Reference standard or comparators Outcomes. Study design Other Title: Strategies for optimizing HIV monitoring among adults, children and pregnant women living with HIV receiving antiretroviral therapy: a systematic review Contents 1. PICO question... 1 2. Search

More information

CURRICULUM VITAE. Miguel Goicoechea, M.D.

CURRICULUM VITAE. Miguel Goicoechea, M.D. CURRICULUM VITAE Miguel Goicoechea, M.D. Office: Telephone: University of California at San Diego Antiviral Research Center 150 West Washington Street, Suite 100 San Diego, CA 92103-2005 (619) 543-8080

More information

Perspective Antiretroviral Therapy: Select Lessons From Recent Studies

Perspective Antiretroviral Therapy: Select Lessons From Recent Studies International AIDS Society USA Topics in HIV Medicine Perspective Antiretroviral Therapy: Select Lessons From Recent Studies Our understanding of HIV pathogenesis continues to evolve and form the foundation

More information

Report Back from CROI 2010

Report Back from CROI 2010 Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco

More information

Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-saharan Africa: a collaborative analysis of scale-up programmes

Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-saharan Africa: a collaborative analysis of scale-up programmes Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-saharan Africa: a collaborative analysis of scale-up programmes Margaret May, Andrew Boulle, Sam Phiri, Eugene Messou,

More information

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord*"

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord* in HIV- Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE The Opportunistic Infections Project Team of the Collaboration of Observational

More information

Intira Jeannie Collins, Ruth Goodall, Colette Smith and Kara Wools-Kaloustian for the CIPHER Duration of First-Line Project Team.

Intira Jeannie Collins, Ruth Goodall, Colette Smith and Kara Wools-Kaloustian for the CIPHER Duration of First-Line Project Team. Switch to second-line ART in HIV-infected children: a Collaborative Initiative for Paediatric HIV Education & Research (CIPHER) Global Cohort Collaboration analysis Intira Jeannie Collins, Ruth Goodall,

More information

Antiviral Therapy 14:

Antiviral Therapy 14: Antiviral Therapy 14:451 457 Short communication CD4 + T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4 + T-cell counts >200 cells/mm

More information

Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery

Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery Clinical Infectious Diseases Advance Access published February 25, 2014 MAJOR ARTICLE HIV/AIDS Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery

More information

The Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4

The Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4 Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish

More information

The EACS Standard of Care initiative. The Standard of Care for HIV and Coinfections in Europe meeting in Rome: a reminder

The EACS Standard of Care initiative. The Standard of Care for HIV and Coinfections in Europe meeting in Rome: a reminder The EACS Standard of Care initiative. The Standard of Care for HIV and Coinfections in Europe meeting in Rome: a reminder Antonella d Arminio Monforte, University of Milan Cristina Mussini, University

More information

Reasons why we will never forget. Andrea Antinori INMI L. Spallanzani IRCCS, Roma

Reasons why we will never forget. Andrea Antinori INMI L. Spallanzani IRCCS, Roma Reasons why we will never forget Andrea Antinori INMI L. Spallanzani IRCCS, Roma SMRs according to time spent with CD4 count >500/mm3 after cart initiation in MSM 80,642 HIV-infected individuals eligible

More information

Epidemiology of ageing with HIV: what can we learn from cohorts?

Epidemiology of ageing with HIV: what can we learn from cohorts? Epidemiology of ageing with HIV: what can we learn from cohorts? Caroline A. Sabin a and Peter Reiss b The last decade has seen a dramatic change in the demographic structure of the population of people

More information

Patients with persistently low CD4 counts on antiretroviral

Patients with persistently low CD4 counts on antiretroviral Predicting HIV Care Costs Using CD4 Counts From Clinical Trials Andrew Hill, PhD; and Kelly Gebo, MD, MPH Objective: To predict the effects of a new antiretroviral agent on the costs of care in a US HIV

More information

Impact on life expectancy of HIV-1 positive individuals of CD4 R cell count and viral load response to antiretroviral therapy

Impact on life expectancy of HIV-1 positive individuals of CD4 R cell count and viral load response to antiretroviral therapy Impact on life expectancy of HIV-1 positive individuals of CD4 R cell count and viral load response to antiretroviral therapy Margaret T. May a, Mark Gompels b, Valerie Delpech c, Kholoud Porter d, Chloe

More information

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study Jonathan A C Sterne, Miguel A Hernán, Bruno Ledergerber, Kate Tilling, Rainer Weber, Pedram

More information

Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town

Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile

More information

Clinical Infectious Diseases Advance Access published June 16, Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?

Clinical Infectious Diseases Advance Access published June 16, Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? Clinical Infectious Diseases Advance Access published June 16, 2015 1 Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? Rochelle P. Walensky, Martin S. Hirsch From the Division of Infectious

More information

HIV Research Network Presentation Abstracts

HIV Research Network Presentation Abstracts HIV Research Network Presentation Abstracts Abstract Title Conference Site Author /Presentation High-risk prescription opioid use among people living with HIV 39th Annual Meeting of the Society of General

More information

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) MAJOR ARTICLE HIV/AIDS Is It Safe to Discontinue Primary Pneumocystis jiroveci Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count!200 Cells/mL? The Opportunistic

More information

Anumber of clinical trials have demonstrated

Anumber of clinical trials have demonstrated IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines

More information

European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe

European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe PANEL MEMBERS Nathan Clumeck, Treasurer Chair, Brussels, Belgium Anton Pozniak,

More information

For any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D,

For any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D, Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Mark Mascolini People who started antiretroviral

More information

Virologic and Immunologic Monitoring

Virologic and Immunologic Monitoring NEW YORK STATE DEPARTMENT OF HEALTH AIDS INSTITUTE HIV HCV SUBSTANCE USE LGBT HEALTH Virologic and Immunologic Monitoring Medical Care Criteria Committee, June 2016 TABLE OF CONTENTS Monitoring Intervals...1

More information

CROI 2017, Seattle, Late Breaker Presentation Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors

CROI 2017, Seattle, Late Breaker Presentation Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors CROI 2017, Seattle, Late Breaker Presentation Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors L Ryom, JD Lundgren, W El-Sadr, P Reiss, A Phillips, O Kirk, R Weber,

More information

Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord

Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Laurence WEISS Hôpital Européen Georges Pompidou, Université Paris-Descartes Paris, France Deaths per 100 Person-Years

More information

Analysis of the pre-art cascade among HIV-infected children aged 0-19 years in the IeDEA global network,

Analysis of the pre-art cascade among HIV-infected children aged 0-19 years in the IeDEA global network, Analysis of the pre-art cascade among HIV-infected children aged 0-19 years in the IeDEA global network, 2004-2014 Sophie Desmonde 1, Frank Tanser 2, Rachel Vreeman 3, Elom Takassi 4, Andrew Edmonds 5,

More information

It has now been 20 years since the first demonstration that antiretroviral drug, azidothymidine,

It has now been 20 years since the first demonstration that antiretroviral drug, azidothymidine, Focused Issue of This Month Antiretroviral Therapy for Treatment of Human Immunodeficiency Virus Type Infection MyungDon Oh, MD Department of Internal Medicine, Seoul National University College of Medicine

More information

This is the author s version of a work that was submitted/accepted for publication in the following source:

This is the author s version of a work that was submitted/accepted for publication in the following source: This is the author s version of a work that was submitted/accepted for publication in the following source: Kelly, Mark D., Gibson, Abby, Bartlett, Harry, Rowling, Diane, & Patten, John (2013) Tenofovir-associated

More information

HIV Update For the Internist

HIV Update For the Internist HIV Update For the Internist Disclosures I declare that I have received no incentives, financial or otherwise, from pharmaceutical or biomedical companies relevant to the content of this talk. As an Infectious

More information

Dr. Mercy Maina, Bpharm Pharmacovigilance Pharmacist USAID- AMPATH 1/17/2014 1

Dr. Mercy Maina, Bpharm Pharmacovigilance Pharmacist USAID- AMPATH 1/17/2014 1 Dr. Mercy Maina, Bpharm Pharmacovigilance Pharmacist USAID- AMPATH 1 Provide a brief description of AMPATH Give a background and description of the project Review the preliminary results Discuss the challenges

More information

ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS

ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS L Ryom, JD Lundgren, W El-Sadr, P Reiss, A Phillips, O Kirk, R Weber, E Fontas, AD Monforte, S de Wit, F Dabis, CI Hatleberg,

More information

Incomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment

Incomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment MAJOR ARTICLE HIV/AIDS Incomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment Colleen F. Kelley, 1,a Christina M. R. Kitchen, 2,a Peter

More information

The use of computational models to predict response to HIV therapy and support optimal treatment selection

The use of computational models to predict response to HIV therapy and support optimal treatment selection The use of computational models to predict response to HIV therapy and support optimal treatment selection Andrew Revell HIV Resistance Response Database Initiative (RDI) London UK Scientific Days of the

More information

Adherence to antiretroviral drugs among AIDS patients in Sagamu, Nigeria

Adherence to antiretroviral drugs among AIDS patients in Sagamu, Nigeria International Journal of Biomedical and Health Sciences 094-44/200 $12.00 + 0.00 Vol. 4, No. 2, June 0, 200 200 African Studies on Population and Health Printed in Nigeria http://www.asopah.org IJBHS 20009/4201

More information

Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality: Swiss HIV Cohort Study

Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality: Swiss HIV Cohort Study Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality: Swiss HIV Cohort Study Tracy R. Glass a,b,c, Jonathan A.C. Sterne d, Marie-Paule Schneider e,f, Sabina

More information

CROI 2016 Review: Immunology and Vaccines

CROI 2016 Review: Immunology and Vaccines Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational

More information

Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study

Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study EPIDEMIOLOGY AND PREVENTION Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study Rebecca A. Legarth, MD, PhD,* Magnus G. Ahlström, MD,* Gitte Kronborg,

More information

A SIMULATION MODEL OF HIV TREATMENT UNDER DRUG SCARCITY CONSTRAINTS. Robert T. Koppenhaver R. Scott Braithwaite Mark Roberts Andrew Schaefer

A SIMULATION MODEL OF HIV TREATMENT UNDER DRUG SCARCITY CONSTRAINTS. Robert T. Koppenhaver R. Scott Braithwaite Mark Roberts Andrew Schaefer Proceedings of the 2009 Winter Simulation Conference M. D. Rossetti, R. R. Hill, B. Johansson, A. Dunkin and R. G. Ingalls, eds. A SIMULATION MODEL OF HIV TREATMENT UNDER DRUG SCARCITY CONSTRAINTS ABSTRACT

More information

Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro,

Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, Martin et al. BMC Infectious Diseases 2014, 14:322 RESEARCH ARTICLE Open Access Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro,

More information

Definitions of antiretroviral treatment failure for measuring quality outcomes

Definitions of antiretroviral treatment failure for measuring quality outcomes DOI: 10.1111/j.1468-1293.2009.00808.x r 2010 British HIV Association HIV Medicine (2010), 11, 427 431 ORIGINAL RESEARCH Definitions of antiretroviral treatment failure for measuring quality outcomes A

More information

Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients?

Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients? Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients? Lars Peters for the hepatitis working group of COHERE in EuroCoord IMIT AMACS ECS-Mothers & ECS-Infants NSHPC-Mothers

More information

Original article Duration of first-line antiretroviral therapy in HIVinfected treatment-naive patients in routine practice

Original article Duration of first-line antiretroviral therapy in HIVinfected treatment-naive patients in routine practice Antiviral Therapy 2016; 21:715 724 (doi: 10.3851/IMP3084) Original article Duration of first-line antiretroviral therapy in HIVinfected treatment-naive patients in routine practice Thomas Tesson 1, Mathieu

More information

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration EPIDEMIOLOGY AND PREVENTION Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration Margaret T. May, PhD,* Amy C. Justice,

More information

Stunting and growth development for adolescents perinatally infected by HIV: males and females evolve differently.

Stunting and growth development for adolescents perinatally infected by HIV: males and females evolve differently. Stunting and growth development for adolescents perinatally infected by HIV: males and females evolve differently. A multiregional analysis from the IeDEA global pediatric collaboration. Julie Jesson,

More information

MDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007

MDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus

More information

Apurba Chakraborty MBBS, MPH Dima M. Qato PharmD, MPH, PhD Professor Mark S. Dworkin MD, MPHTM The University of Illinois at Chicago

Apurba Chakraborty MBBS, MPH Dima M. Qato PharmD, MPH, PhD Professor Mark S. Dworkin MD, MPHTM The University of Illinois at Chicago Less is More: The Impact of Lower Pill Burden on Adherence to Antiretroviral Therapy among Treatment-Naive Patients with HIV Infection in the United States Apurba Chakraborty MBBS, MPH Dima M. Qato PharmD,

More information

NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2012 September 1.

NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2012 September 1. NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2011 September 1; 58(1): 72 79. doi:10.1097/qai.0b013e318225ba62. CD4 CELL RESPONSES TO COMBINATION ANTIRETROVIRAL

More information

ORIGINAL INVESTIGATION

ORIGINAL INVESTIGATION ORIGINAL INVESTIGATION Effect of Antiretroviral Therapy on Viral Load, CD4 Cell Count, and Progression to Acquired Immunodeficiency Syndrome in a Community Human Immunodeficiency Virus Infected Cohort

More information

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts 1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion

More information

The role of a Pharmacist in the analysis of adherence rates and associated factors in HIV-patients registered on Centralized Chronic Medicines

The role of a Pharmacist in the analysis of adherence rates and associated factors in HIV-patients registered on Centralized Chronic Medicines The role of a Pharmacist in the analysis of adherence rates and associated factors in HIV-patients registered on Centralized Chronic Medicines Dispensing and Distribution (CCMDD) programme in the public

More information

Single Viral Load Measurements Overestimate Stable Viral Suppression Among HIV Patients in Care: Clinical and Public Health Implications

Single Viral Load Measurements Overestimate Stable Viral Suppression Among HIV Patients in Care: Clinical and Public Health Implications EPIDEMIOLOGY AND PREVENTION Single Viral Load Measurements Overestimate Stable Viral Suppression Among HIV Patients in Care: Clinical and Public Health Implications Gary Marks, PhD,* Unnati Patel, MPH,

More information

The effect of depression on missed HIV medical visits among patients in the CFAR Network of Integrated Systems (CNICS) cohort in the United States

The effect of depression on missed HIV medical visits among patients in the CFAR Network of Integrated Systems (CNICS) cohort in the United States The effect of depression on missed HIV medical visits among patients in the CFAR Network of Integrated Systems (CNICS) cohort in the United States Brian Pence*, Angela Bengtson, Katerina Christopoulos,

More information

Women with a history of injection drug use at greatest risk for poorer clinical outcomes in a cohort of HIV-positive individuals in Canada

Women with a history of injection drug use at greatest risk for poorer clinical outcomes in a cohort of HIV-positive individuals in Canada Women with a history of injection drug use at greatest risk for poorer clinical outcomes in a cohort of HIV-positive individuals in Canada Angela Cescon, Alexis K Palmer, Keith Chan, Shari Margolese, Janet

More information

COMPETING INTEREST OF FINANCIAL VALUE

COMPETING INTEREST OF FINANCIAL VALUE BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Duncan Churchill Royal Sussex County Hospital, Brighton COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Duncan Churchill

More information

CLASSIFICATION AND REGRESSION TREE IN PREDICTION OF SURVIVAL OF AIDS PATIENTS

CLASSIFICATION AND REGRESSION TREE IN PREDICTION OF SURVIVAL OF AIDS PATIENTS CLASSIFICATION AND REGRESSION TREE IN PREDICTION OF SURVIVAL OF AIDS PATIENTS Sameem Abdul Kareem*, S. Raviraja*, Namir A Awadh*, Adeeba Kamaruzaman**, Annapurni Kajindran** ABSTRACT *Department of Artificial

More information

HIV-1 related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4 T-cell lymphocytes

HIV-1 related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4 T-cell lymphocytes CLINICAL TRIALS AND OBSERVATIONS HIV-1 related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4 T-cell lymphocytes Julia Bohlius, 1 Kurt Schmidlin, 1 François

More information

Clinical Case. Prof.ssa Cristina Mussini

Clinical Case. Prof.ssa Cristina Mussini Clinical Case Prof.ssa Cristina Mussini Clinical history Male, born in Ivory Coast in 1968. HIV positive since dal 1998 Risk factor: heterosexual contacts He started antiretroviral therapy in 2001 with

More information

Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?

Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical

More information

Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D Study

Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D Study Email: leah.shepherd@ucl.ac.uk CROI 2017 Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D Study Leah Shepherd 1, Lene Ryom 2, Kathy Petoumenos 3, Camilla Ingrid Hatleberg

More information

When to start: guidelines comparison

When to start: guidelines comparison The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count

More information

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline

More information

Factors Predicting Discordant Virological and Immunological Responses to Antiretroviral Therapy in HIV-1 Clade C Infected Zulu/Xhosa in South Africa

Factors Predicting Discordant Virological and Immunological Responses to Antiretroviral Therapy in HIV-1 Clade C Infected Zulu/Xhosa in South Africa Factors Predicting Discordant Virological and Immunological Responses to Antiretroviral Therapy in HIV-1 Clade C Infected Zulu/Xhosa in South Africa The Harvard community has made this article openly available.

More information

Efficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results

Efficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results Efficacy and Safety of Doravirine 1mg QD vs Efavirenz 6mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results Jose M. Gatell, Francois Raffi, Andreas Plettenberg, Don Smith, Joaquin Portilla,

More information

Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cart)

Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cart) The Open AIDS Journal, 2008, 2, 3-9 3 Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cart) Marguerite Guiguet *,1,2, Kholoud Porter

More information

HIV AND CEREBROVASCULAR DISEASE: AN INTERSECTION OF EPIDEMICS

HIV AND CEREBROVASCULAR DISEASE: AN INTERSECTION OF EPIDEMICS HIV AND CEREBROVASCULAR DISEASE: AN INTERSECTION OF EPIDEMICS Felicia C. Chow, MD, MAS University of California, San Francisco Departments of Neurology and Medicine (Infectious Diseases) September 26,

More information

Test & Treat : Changing the face of insurance for persons living with HIV?

Test & Treat : Changing the face of insurance for persons living with HIV? Test & Treat : Changing the face of insurance for persons living with HIV? Kadene Gibbs FSA, MSc Dr Matthew Procter Agenda 1. Background 2. Understanding HIV and Factors affecting Prognosis 3. History

More information

New options for new and old patients. Antonella Castagna

New options for new and old patients. Antonella Castagna New options for new and old patients Antonella Castagna Disclosures I have received funding for Advisory Boards, Speaker Panels and for preparation of educational materials from the following: Gilead Sciences

More information

Marked and sustained reductions in AIDS-related death and

Marked and sustained reductions in AIDS-related death and PEN.012.1092 CLINICAL SCIENCE Mortality in the Highly Active Antiretroviral Therapy Era Changing Causes of Death and Disease in the HIV Outpatient Study Frank J. Palella, Jr., MD,* Rose K. Baker, MA,Þ

More information

15 years Follow Up in a Cohort of Children diagnosed with HIV Cardiomyopathy

15 years Follow Up in a Cohort of Children diagnosed with HIV Cardiomyopathy 15 years Follow Up in a Cohort of Children diagnosed with HIV Cardiomyopathy Lecturer Ana Maria TudorMD PhD * Mariana Mărdărescu MD PhD * Professor Ioana Anca MD PhD * * National Institute for Infectious

More information

The advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD

The advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with

More information

Evolving Realities of HIV Treatment in Resource-limited Settings

Evolving Realities of HIV Treatment in Resource-limited Settings Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has

More information

Newly HIV diagnosed in South Sardinia: the issue of late presentation

Newly HIV diagnosed in South Sardinia: the issue of late presentation Infect Dis Trop Med 2016; 2 (2): e291 Newly HIV diagnosed in South Sardinia: the issue of late presentation G. Angioni 1, N. Cesta 2, T. Mulas 3, M. Sedda 3, S. Piga 1 1 Infectious Diseases Department,

More information

Journal Journal of Acquired Immune Deficiency Syndromes (1999) Archived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)

Journal Journal of Acquired Immune Deficiency Syndromes (1999) Archived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999) MSF Field Research CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa Authors Citation DOI Publisher Hoffmann, Christopher J; Schomaker,

More information

Review Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation

Review Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation Antiviral Therapy 2010 15 Suppl 1:31 35 (doi: 10.3851/IMP1525) Review Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation Andrea Antinori

More information